From diagnosis methods to management of comorbid infections, new lung cancer protocols adaptable for various conditions ...

Positive high-level results from the final overall survival (OS) analysis of the FLAURA2 Phase III trial showed AstraZeneca’s TAGRISSO® (osimertinib) with the addition of pemetrexed and platinum-based ...

FDA designates T-DXd plus pertuzumab as breakthrough therapy for HER2-positive metastatic breast cancer, promising improved survival rates for patients.

Non-small cell lung cancer (NSCLC) develops in lung tissues, but when it's metastatic, it has spread to distant areas of the ...

After the approval of immune checkpoint inhibitors, overall survival among US patients with advanced-stage cancer improved, but disparities between uninsured and privately insured widened.

Cancer patients without health insurance have not derived the same benefits from the introduction of ICIs as patients with private insurance.

The age-adjusted cancer death rate has fallen since the 1990s, with the world winning the so-called "war on cancer." ...

The trial's principal investigator Pasi Janne said the results support osimertinib "as standard of care" for EGFR-mutated cancer patients. Janne also noted that AstraZeneca's drug "did not impose any ...

They want to gain a deeper understanding of why the disease behaves differently in these patients. Read more at ...

A Flinders University study shows that bowel cancer survivors face an elevated risk of developing multiple primary cancers ...

Eligible Triad patients include those with a family history of pancreatic cancer or an increased risk based on genetic ...